GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results
One of the spillover effects of the COVID-19 pandemic has been the increase in opioid-related deaths. These deaths overwhelmingly affect working-class Americans with limited access and.
NICE uphold appeal by Kyowa Kirin, for POTELIGEO in the treatment of those living with certain ultra-rare blood cancers The National Institute for Health and Care Excellence (NICE) has upheld an appeal
Wednesday, June 9, 2021
One of the spillover effects of the COVID-19 pandemic has been the increase in opioid-related deaths. These deaths overwhelmingly affect working-class Americans with limited access and resources to lifesaving drugs such as buprenorphine and naloxone. As a result, the Department of Health and Human Services (HHS) issued the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guidelines) through a waiver of certain certification requirements prescribed by law. The Practice Guidelines remove a longtime prerequisite tied to training and counseling that several practitioners have cited as a barrier to treating patients with Opioid Use Disorder (OUD). The Practice Guidelines could not come soon enough, as a recent study indicates that individuals with OUD experienced decreased access to treatments during the pandemic.